Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial

Abstract Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and c-Kit. This phase II study aimed to assess the efficacy an...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Shuangshuang Zhao, Minmin Zhang, Qing Zhang, Jingjun Wu, Hui Dai
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2024-01-01
Schriftenreihe:	BMC Cancer
Schlagworte:	Anlotinib Bevacizumab Multi-target tyrosine kinase inhibitor Recurrent high-grade glioma
Online-Zugang:	https://doi.org/10.1186/s12885-023-11776-4
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!